A detailed history of Kennedy Capital Management, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 41,961 shares of VKTX stock, worth $2.29 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
41,961
Previous 46,986 10.69%
Holding current value
$2.29 Million
Previous $2.49 Million 6.67%
% of portfolio
0.06%
Previous 0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $250,446 - $354,111
-5,025 Reduced 10.69%
41,961 $2.66 Million
Q2 2024

Aug 14, 2024

SELL
$47.39 - $80.2 $435,277 - $736,637
-9,185 Reduced 16.35%
46,986 $2.49 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $791,995 - $4.3 Million
-45,517 Reduced 44.76%
56,171 $4.61 Million
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $939,597 - $2 Million
101,688 New
101,688 $1.89 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.18B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.